Cassava Sciences Inc (NQ: SAVA )
24.01 +0.70 (+3.00%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Press Releases about Cassava Sciences Inc
Cassava Sciences Announces Expansion of Leadership Team
October 27, 2022
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Cassava Sciences Responds to Media Reports
July 27, 2022
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Cassava Sciences, Inc. (NASDAQ:SAVA) Investor Alert: Investigation over Possible Violations of Securities Laws
June 02, 2022
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Cassava Sciences, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster...
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following